{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:48:07Z","timestamp":1783471687064,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contraceptionjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.contraception.2016.01.012","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T16:01:26Z","timestamp":1453824086000},"page":"378-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives"],"prefix":"10.1016","volume":"93","author":[{"given":"J\u00fcrgen","family":"Dinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"M\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2016.01.012_bb0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European active surveillance study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.01.012_bb0010","article-title":"A household panel as a tool for cost-effective health-related population surveys: validity of the Healthcare Access Panel","volume":"2","author":"Potthoff","year":"2004","journal-title":"Ger Med Sci"},{"key":"10.1016\/j.contraception.2016.01.012_bb0015","series-title":"Surveys in public health \u2013 developments and perspectives in research and political counseling","first-page":"91","article-title":"Access panel \u2013 quality aspects and experience","author":"G\u00fcther","year":"2005"},{"key":"10.1016\/j.contraception.2016.01.012_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1515\/pubhef-2005-2191","article-title":"Access panel in the context of health research","volume":"13","author":"Potthoff","year":"2005","journal-title":"Forum Public Health"},{"key":"10.1016\/j.contraception.2016.01.012_bb0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.contraception.2014.01.023","article-title":"Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the international active surveillance study of women taking oral contraceptives","volume":"89","author":"Dinger","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.01.012_bb0030","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/AOG.0b013e3182a5ec6b","article-title":"Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring","volume":"122","author":"Dinger","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2016.01.012_bb0035","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/oxfordjournals.aje.a115939","article-title":"What is a cause and how do we know one? A grammar for pragmatic epidemiology","volume":"133","author":"Susser","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2016.01.012_bb0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/ije\/17.4.955","article-title":"A strengthening programme for weak associations","volume":"17","author":"Rothman","year":"1988","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.contraception.2016.01.012_bb0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/tera.1420460110","article-title":"Interpretation of recurring weak associations obtained from epidemiologic studies of suspected human teratogens","volume":"46","author":"Khoury","year":"1992","journal-title":"Teratology"},{"key":"10.1016\/j.contraception.2016.01.012_bb0050","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/oxfordjournals.aje.a010135","article-title":"Bias in the evaluation of low-magnitude associations: an empirical perspective","volume":"151","author":"Shapiro","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2016.01.012_bb0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1783\/147118908784734873","article-title":"Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. Part 2. Principles of causality in epidemiological research: confounding, effect modification and strength of association","volume":"34","author":"Shapiro","year":"2008","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2016.01.012_bb0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1783\/147118908786000596","volume":"34","author":"Shapiro","year":"2008","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2016.01.012_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.01.012_bb0070","first-page":"1816","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"Oelkers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2016.01.012_bb0075","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjhyper.2004.12.003","article-title":"Effects of drospirenone\/17-\u00df estradiol on blood pressure and potassium balance in hypertensive postmenopausal women","volume":"18","author":"Preston","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.contraception.2016.01.012_bb0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000232179.60442.84","article-title":"Effects of a new hormone therapy, drospirenone and17-\u00df-estradiol, in postmenopausal women with hypertension","volume":"48","author":"White","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.contraception.2016.01.012_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"NEJM"},{"key":"10.1016\/j.contraception.2016.01.012_bb0090","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"NEJM"},{"issue":"Suppl. 1","key":"10.1016\/j.contraception.2016.01.012_bb0095","first-page":"214","article-title":"EURAS-HRT: Cardiovascular and other outcomes","volume":"14","author":"Dinger","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.contraception.2016.01.012_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.contraception.2012.09.015","article-title":"Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users","volume":"87","author":"Sidney","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.01.012_bb0105","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.AOG.0000279448.62221.a8","article-title":"Risk of thromboembolism in women taking ethinylestradiol\/drospirenone and other oral contraceptives","volume":"110","author":"Seeger","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2016.01.012_bb0110","first-page":"S114","article-title":"Case\u2013control study: use of oral contraceptives containing dienogest and risk of venous thromboembolism","volume":"18","author":"Dinger","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.contraception.2016.01.012_bb0115","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2016.01.012_bb0120","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case\u2013control study using United States claims data","volume":"340","author":"Jick","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2016.01.012_bb0125","doi-asserted-by":"crossref","first-page":"d2139","DOI":"10.1136\/bmj.d2139","article-title":"Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case\u2013control study based on UK general practice research database","volume":"340","author":"Parkin","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2016.01.012_bb0130","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case\u2013control study","volume":"339","author":"Van Hylckama","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2016.01.012_bb0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jfprhc-2011-100260","article-title":"Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets","volume":"38","author":"Dinger","year":"2012","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2016.01.012_bb0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1783\/147118910791749425","article-title":"Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in berlin, Germany in December 2009","volume":"36","author":"Reid","year":"2010","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2016.01.012_bb0145","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/AOG.0b013e3181f98300","article-title":"Epidemiologic research using administrative databases: garbage in, garbage out","volume":"116","author":"Grimes","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2016.01.012_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2016.01.012_bb0155","first-page":"126","article-title":"Contraception and thrombophilia - a statement from the German society for gynecological endocrinology and reproductive medicine (DGGEF e.V.) and the professional association of German gynaecologists","volume":"8","author":"Rabe","year":"2011","journal-title":"J Reproduktionsmed Endokrinol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416000329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416000329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:17:37Z","timestamp":1654175857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782416000329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0010782416000329"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2016.01.012","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2016.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}